1st Aug 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, and medac GmbH, an international pharmaceutical company based in Germany, will partner to commercialize Glycostem’s lead product, oNKord®. oNKord® is currently in a phase I/II clinical trial across 10 hospitals in 5 European countries.
Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients. Glycostem will receive an undisclosed upfront payment and through the manufacturing of oNKord® a part of future revenues. Glycostem will also be eligible for payments upon achievement of certain development and sales milestones.
For more information see the Glycostem website.